Payment overview · 2025
General Payments
$594.34
32 reported records · 13 companies
Healthcare provider profile · identity verified
Brandon Doverspike, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLARION, PA · NPI 1962811497
Verified facts
What the public records show
CMS Open Payments records show Brandon Doverspike, D.O. received $594.34 in general payments during 2025 across 32 reported records.
Novo Nordisk Inc accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.53 | 25.3% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $83.12 | 14.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.80 | 13.8% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.86 | 8.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.85 | 6.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.19 | 5.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.06 | 5.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.22 | 5.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.01 | 3.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.84 | 3.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.25 | 3.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.17 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.44 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $594.34 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $86.56 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $83.12 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.80 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.97 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $52.86 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.85 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.06 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.22 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 55 |
| Lisinopril | Lisinopril | 202 | 50 |
| Metformin Hcl | Metformin Hcl | 170 | 36 |
| Omeprazole | Omeprazole | 165 | 37 |
| Eliquis | Apixaban | 162 | 24 |
| Furosemide | Furosemide | 162 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 29 |
| Losartan Potassium | Losartan Potassium | 134 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 23 |
| Gabapentin | Gabapentin | 102 | 24 |
| Trazodone Hcl | Trazodone Hcl | 98 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 22 |
| Simvastatin | Simvastatin | 89 | 25 |
| Montelukast Sodium | Montelukast Sodium | 88 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 16 |
| Sertraline Hcl | Sertraline Hcl | 78 | 16 |
| Meloxicam | Meloxicam | 77 | 22 |
| Jardiance | Empagliflozin | 72 | 19 |
| Alendronate Sodium | Alendronate Sodium | 70 | 14 |
| Lorazepam | Lorazepam | 70 | 27 |
| Potassium Chloride | Potassium Chloride | 68 | 17 |
| Prednisone | Prednisone | 67 | 35 |
| Celecoxib | Celecoxib | 66 | 14 |
| Donepezil Hcl | Donepezil Hcl | 65 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 11 |
| Glimepiride | Glimepiride | 61 | 19 |
| Buspirone Hcl | Buspirone Hcl | 60 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 52 | 21 |
| Allopurinol | Allopurinol | 50 | 11 |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | suppressed |
| Famotidine | Famotidine | 49 | 11 |
| Alprazolam | Alprazolam | 46 | 11 |
| Bumetanide | Bumetanide | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Sucralfate | Sucralfate | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 15 |
| Carvedilol | Carvedilol | 41 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Calcium Acetate | Calcium Acetate | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 14 |
| Ozempic | Semaglutide | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 23 |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 14 |
| Colchicine | Colchicine | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $594.34 · 32 records | Novo Nordisk Inc | CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, Ozempic, PROLIA, QULIPTA, REXULTI, ROTATEQ, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error